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Abstract
Purpose We examined the safety and eYcacy of the
combination of S-1 and biweekly docetaxel in patients with
previously treated advanced non-small-cell lung cancer
(NSCLC).
Methods Patients with previously treated advanced
NSCLC were eligible if they had a performance status of 2
or less, were 80 years or younger, and had adequate organ
function. Forty-nine patients (38 men and 11 women;
median age, 66 years; range 43–79 years) were enrolled.
Patients were treated with the combination of 80 mg/m2 per
day of S-1 for 14 consecutive days and 35 mg/m2 of doce-
taxel on days 1 and 15 every 4 weeks.
Results The overall response rate was 16.3% (95% conW-
dence interval, 7.6–30.5%). The disease-control rate was
49.0% (95% conWdence interval, 34.4–63.7%). The median
survival time after this treatment was 9 months (range
1–22 months). The median progression-free survival time was
3 months (range 1–11 months). Response rates and survival
times did not diVer signiWcantly according to the histologi-
cal type. Grade 3–5 toxicities included neutropenia in
51.0% of patients, thrombocytopenia in 2.0%, anemia in
20.4%, infection in 24.5%, anorexia in 12.2%, diarrhea in
14.3%, nausea in 6.1%, and dehydration in 4.2%. There
was 1 treatment-related death due to severe anorexia,
stomatitis, diarrhea, and, as consequence, dehydration.
Conclusions The combination of S-1 and biweekly doce-
taxel is an acceptable therapeutic option in patients with
previously treated advanced NSCLC regardless of the
histological type.
Keywords S-1 · Docetaxel · Second-line chemotherapy · 
Non-small-cell lung cancer
Introduction
Although platinum-based chemotherapy improves survival
over best supportive care for patients with chemotherapy-
naïve advanced non-small-cell lung cancer (NSCLC) [1],
almost all patients relapse after receiving Wrst-line chemo-
therapy. The prognosis of patients who have relapsed
or have refractory NSCLC and do not receive additional
therapy is extremely poor: median survival time (MST) is
reported to be only 4–5 months [2, 3]. On the other hand,
many patients maintain a good performance status (PS) and
have adequate organ function. Thus, second-line chemo-
therapy is an important treatment for patients with previ-
ously treated advanced NSCLC.
Docetaxel promotes microtubule assembly and inhibits
depolymerization to free tubulin, which results in the arrest
of the cell cycle in the M phase [4]. In 2 phase III trials in
patients with NSCLC previously treated with a platinum-
based regimen, docetaxel confers greater survival and clini-
cal beneWts and improves quality of life to a greater degree
than does best supportive care or monotherapy with vino-
relbine or ifosfamide [2, 5]. As a result of these randomized
trials, docetaxel has become one of standard treatments for
NSCLC refractory to platinum-based agents. However,
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these trials yielded unsatisfactory results, with response
rates of approximately 7%, time to progression of 10.6 and
8.5 weeks, MSTs of 7.5 and 5.7 months, and 1-year sur-
vival rates of 37 and 32%, respectively [2, 5].
S-1 was developed to enhance the eYcacy and reduce
the toxicity of 5-Xuorouracil (5-FU). S-1 is an oral Xuoro-
pyrimidine agent that consists of tegafur, which is a prodrug
of 5-FU, and two biochemical modulators, 5-chloro-2,
4-dihydroxypyridine (CDHP), and potassium oxonate in a
molar ratio of 1:0.4:1 [6]. CDHP competitively inhibits
dihydropyrimidine dehydrogenase, a key enzyme for 5-FU
degradation, and enhances the anticancer activity of 5-FU.
Potassium oxonate inhibits the phosphorylation of 5-FU in
the gut by inhibiting the enzymatic pyrimidine phosphori-
bosyl transferase pathway and reduces the gastrointestinal
toxicity of active 5-FU without interfering with its antitu-
mor activity [7]. S-1 monotherapy has achieved an overall
response rate of 22% and a MST of 11 months with few
severe gastrointestinal or hematologic adverse events in
patients with advanced NSCLC [8].
In preclinical studies, docetaxel has shown no cross-
resistance in 5-FU-resistant human tumor cell lines [9].
Additionally, the combination of S-1 and docetaxel has
been reported to have synergistic eVects in vitro [10].
Moreover, in xenograft models of gastric and breast can-
cer the combination of S-1 and docetaxel has shown syn-
ergistic antitumor activity compared with monotherapy
with either drug [11, 12]. Furthermore, S-1 and docetaxel
have diVerent mechanisms of action and safety proWles
and show no pharmacokinetic interaction [11]. Therefore,
the doublet combination chemotherapy of S-1 and doce-
taxel would be more eVective than docetaxel mono-
therapy.
Several phase II studies have found that the combina-
tion of docetaxel and S-1 is eVective in patients with lung
or gastric cancer [13–16]. A phase I trial of the combina-
tion of biweekly docetaxel and S-1 for recurrent
advanced gastric cancer has recommended dose levels
for phase II studies of 35 mg/m2 of docetaxel on days 1
and 15 in combination with 80 mg/m2 per day of S-1 for
14 consecutive days every 4 weeks [17]. However, no tri-
als have evaluated the combination of S-1 and biweekly
docetaxel in patients with previously treated advanced
NSCLC. Therefore, we performed the present phase II
study to assess the antitumor activity and toxicity of S-1
and biweekly docetaxel, with dose levels based on the
above phase I study, in patients with previously treated
advanced NSCLC. The primary end point of present
phase II study was to assess the response rates, and the
secondary endpoints were to assess the safety, progres-
sion-free survival, and overall survival of S-1 and
biweekly docetaxel in patients with previously treated
advanced NSCLC.
Patients and methods
Eligibility criteria
Patients with NSCLC who had previously received cyto-
toxic chemotherapy were enrolled. The criteria for study
entry were as follows: (1) histologically or cytologically
conWrmed NSCLC; (2) stage III or IV disease; (3) age 80 or
less; (4) Eastern Cooperative Oncology Group PS of 2 or
less; (5) measurable or assessable lesions; (6) life expec-
tancy of at least 8 weeks; (7) adequate bone marrow func-
tion (white blood cell count of 4,000–12,000/l, neutrophil
count of 2,000/l or more, platelet count of 100,000/l or
more, and hemoglobin level of 9 g/dl or more), hepatic
function (total serum bilirubin level less than the upper
limit of the normal range, levels of aspartate aminotransfer-
ase and alanine aminotransferase less than or equal to twice
the upper limits of the normal ranges), and renal function
(serum creatinine level less than 1.5 mg/dl and creatinine
clearance rate of 50 ml/min or more). Patients were
excluded if they had pulmonary Wbrosis or interstitial pneu-
monia, severe heart disease, active infection, severe drug
allergy, other serious underlying medical conditions, symp-
tomatic brain metastasis, or an active second malignancy.
The study protocol was approved by the ethics committee
of Showa University School of Medicine, and all patients
provided written informed consent.
Treatment schedule
S-1 was given orally twice daily after a meal for 14 consec-
utive days, followed by 14 days of rest. The dose of S-1
(80 mg/m2 per day) was simpliWed according to body sur-
face area (BSA) as follows: 80 mg/day for patients with a
BSA of less than 1.25 m2, 100 mg/day for those with a BSA
of 1.25–1.5 m2, and 120 mg/day for those with a BSA
greater than 1.5 m2. Docetaxel (35 mg/m2) was diluted in
500 ml of normal saline and given as an intravenous drip
infusion over 60 min on days 1 and 15. This regimen was
repeated every 4 weeks for a maximum of six courses. Che-
motherapy was discontinued for grade 3 or higher nonhema-
tologic toxicity, except for nausea/vomiting, anorexia,
stomatitis, diarrhea, constipation, alopecia, or fatigue at any
time, or if the treatment outcome was progressive disease at
any time. If 2 or more weeks had passed after the scheduled
start of the next course until these criteria were satisWed, the
patient left the study at that time but was still included in the
analysis. If there was stable disease after two courses, subse-
quent therapy was left to the discretion of the physician in
charge of the patient. Palliative radiotherapy was permitted
to control persistent pain associated with bone metastasis.
The next course of treatment was started when the neu-
trophil count returned to 1,500/l, the platelet count returnedCancer Chemother Pharmacol (2011) 67:791–797 793
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to 75,000/l, and the nonhematologic toxicity recovered to
grade 0 or 1. Administration of S-1 was stopped if the neu-
trophil count was less than 500/l or if the platelet count
was less than 20,000/l and was restarted when neutrophil
count returned to 1,500/l and the platelet count returned to
75,000/l. Administration of docetaxel was delayed 1 week
if the neutrophil count was less than 1,000/l or if the plate-
let count was less than 75,000/l, and the dose of docetaxel
was omitted if the neutrophil count or the platelet count had
not recovered by 1 week later. If administration of docetaxel
was delayed 1 week, administration of S-1 at the next course
was also delayed 1 week. Additionally, if administration of
S-1 was stopped, and delayed the last planned dose of S-1,
administration of docetaxel at the next course was also
delayed according to the day of the last administration of S-1.
If grade 2 nonhematologic toxicities, except for nausea, anor-
exia, fatigue, alopecia, or hepatic dysfunction, occurred,
administration of S-1 was continued but doses were reduced
by 20 mg/day. For the next course, docetaxel doses were
reduced by 5 mg/m2, and S-1 doses were reduced by 20 mg/
day if the patient had grade 4 neutropenia lasting 3 days or
longer, grade 4 thrombocytopenia, or grade 3 or 4 neutro-
penia associated with a fever higher than 38°C. The S-1
doses were reduced by 20 mg/day if S-1 administration was
stopped for longer than 8 days. Dexamethasone and the anti-
emetic medication ondansetron were given prophylactically
to all patients before docetaxel administration. To prevent
and counteract neutropenia, we routinely used granulocyte
colony-stimulating factor until neutrophil counts had
returned to the normal range in patients with grade 4 leuko-
penia or neutropenia, according to the guideline of the Japa-
nese Ministry of Health, Labour and Welfare.
Evaluation
Evaluation before treatment included a baseline history and
physical examination, complete blood count with diVeren-
tial, routine chemistry proWles, chest radiography, com-
puted tomography of the chest and abdomen, magnetic
resonance or computed tomography of the brain, and a radi-
onucleotide bone scan. Complete blood counts with diVer-
ential and routine chemistry proWles were determined at
least once a week during chemotherapy. Chest radiography
was performed once per week during chemotherapy, and
electrocardiography was performed before and after che-
motherapy.
Tumors were measured after the second, fourth, and
sixth courses. Tumor response was classiWed according to
Response Evaluation Criteria in Solid Tumors (RECIST
Guidelines) [18]. Toxicities were assessed and graded
according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 3.0. All patients
who had received at least 2 courses of chemotherapy were
assessable for response, and all patients who had received
at least 1 course of chemotherapy were assessable for toxic-
ity and survival.
Statistical methods
The trial was designed as a phase II study, with response
rate as the main endpoint. We chose a 30% response rate as
a desirable target level and a 10% response rate as undesir-
able. The study design had a power of greater than 90% to
detect a response with an error of less than 5%. Therefore,
we required 42 assessable patients according to Simon’s
minimax design.
Progression-free survival (PFS) time was deWned as the
period from the start of this treatment to the identiWable
time for Wrst progression or death from any cause. Survival
time was measured from the start of the present treatment
until death or last follow-up. Survival curves were con-
structed with the Kaplan–Meier method and were analyzed
with the log-rank test. The chi-square test was used to
determine the signiWcance of diVerences in response rates
between squamous cell carcinoma and other types of cancer
and between patients who received and did not receive pac-
litaxel pretreatment and of diVerences in toxicity between
patients of diVerent age. DiVerences with a p value <0.05
were considered statistically signiWcant.
Results
Patients characteristics
From October 2006 through March 2009, 49 patients were
enrolled (Table 1). Of these 49 patients, 16 (32.7%) were
70 years or older and 7 (14.3%) had a PS of 2. The median
time from the end of the last previous chemotherapy to the
present treatment was 5 months (range 0.5–31 months).
Toxicity and survival could be assessed in all 49 patients,
and response could be assessed in 45 patients. Four patients
could not be evaluated for response because they had not
received two courses of chemotherapy owing to their gen-
eral condition having rapidly deteriorated after receiving
chemotherapy (three patients) and to patient refusal (one
patient). These patients were considered not evaluable, i.e.,
they were included in the denominator but not in the
numerator in calculations of the response rate and the dis-
ease-control rate.
Treatments before or after the present treatment
All patients had received a platinum-containing regimen as
Wrst-line chemotherapy: carboplatin and vinorelbine (13
patients), cisplatin and vinorelbine (11 patients), nedaplatin794 Cancer Chemother Pharmacol (2011) 67:791–797
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and paclitaxel (10 patients), nedaplatin and gemcitabine
(7 patients), carboplatin and gemcitabine (5 patients), and
carboplatin and paclitaxel (3 patients). Thus, 10 patients had
previously been treated with paclitaxel. All 7 patients who
underwent this treatment as third-line chemotherapy had
previously received geWtinib or erlotinib, which are epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibi-
tors, as second-line therapy. After this treatment, 14 (29%)
patients received an EGFR tyrosine kinase inhibitor alone,
10 (35%) patients received cytotoxic chemotherapy alone,
and seven patients (20%) received both an EGFR tyrosine
kinase inhibitor and cytotoxic chemotherapy.
Treatment response and survival
Of the 49 patients, 1 (2.0%) achieved a complete response,
7 (14.3%) achieved a partial response, 16 (32.6%) had sta-
ble disease, 21 (42.9%) had progressive disease, and 4
(8.2%) were not evaluable, for an overall response rate of
16.3% [95% conWdence interval (CI), 7.3–29.7%]. The
disease-control rate was 49.0% (95% CI, 34.4–63.7%).
Response rates were 14.7% for adenocarcinoma, 18.2% for
squamous cell carcinoma, and 25.0% for other types and
did not diVer signiWcantly according to the histological type
(p = 0.95). Response rate did not diVer signiWcantly
between patients who had received paclitaxel pretreatment
(15.4%) and patients who had not (16.7%, p = 0.62).
Survival analysis was performed when the median fol-
low-up time of all evaluable patients was 9 months. At the
time of analysis, nine patients (18.4%) were alive and none
had been lost to follow-up. The MST from the start of this
regimen was 9 months (range 1–22 months; Fig. 1). The
1-year survival rate from the start of this regimen was 42%.
The MST did not diVer signiWcantly according to the histo-
logical type (p = 0.28). The MST did not diVer signiWcantly
between patients who had received paclitaxel pretreatment
and patients who had not (p = 0.35). The median PFS time
was 3 months (range 1–15 months; Fig. 2).
Toxicity
Table 2 lists the worst-grade toxicities developing during
treatment. Grade 3–4 hematologic toxicities included neu-
tropenia in 51.0% of patients, thrombocytopenia in 2.0%,
and anemia in 20.4%. Granulocyte colony-stimulating fac-
tor was given during 20.7% of courses (25 of 121 courses;
median duration of administration, 3 days; range 1–8 days).
One patient received platelet transfusions, and 4 patients
Table 1 Patients characteristics
Total number of patients 49
Sex (M/F) 38/11
Age, years (range) 66 (43–79)
Performance status at relapse (0/1/2) 4/38/7
Stage at relapse (IIIA/IIIB/IV) 3/7/39
Histologic type
Adenocarcinoma 34
Squamous 11
Large 2
Others 2
Number of prior regimens of chemotherapy (1/2) 42/7
Thoracic radiation therapy (yes/no) 22/27
Response to previous chemotherapy
Complete response 5
Partial response 23
Stable disease 7
Progressive disease 13
Not evaluable 1
Fig. 1 The Wgure shows overall survival from this treatment estimated
with the Kaplan–Meier method. The median survival time was
9 months (range 1–22 months)
Fig. 2 The Wgure shows progression-free survival time from this treat-
ment estimated with the Kaplan–Meier method. The median progres-
sion-free survival time was 3 months (range 1–11 months)Cancer Chemother Pharmacol (2011) 67:791–797 795
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received erythrocyte transfusions. No patients had severe
complications related to myelosuppression.
Although the most frequent nonhematologic toxicities
were electrocyte abnormalities, all electrocyte abnormali-
ties resolved soon without medication or hydration. Grade
3–5 nonhematologic toxicities included infection in 24.5%
of patients, anorexia in 12.2%, diarrhea in 14.3%, nausea in
6.1%, and dehydration in 4.2%. Although 1 patient had
grade 3 pulmonary toxicity due to Pneumocystis carinii
pneumonia during the second course, this patient recovered
after receiving trimethoprim–sulfamethoxazole, corticoste-
roids, and supplemental oxygen. There was no drug-induced
pneumonitis. On the other hand, there was 1 treatment-
related death. This patient was a 71-year-old man with a PS of
1 and normal renal function, who died during the second
course, because of stomatitis and diarrhea, and, as conse-
quence, dehydration developed after the completion of
administration of S-1 for 14 consecutive days and adminis-
tration of docetaxel on days 1 and 15.
Table 3 shows the frequency of toxicity according to
age. Stomatitis, dehydration, and infection were signiW-
cantly more frequent in patients 70 years or older than in
patients younger than 70 years.
Dose intensity
A total of 121 courses of chemotherapy were given. The
median number of courses given per patient was 2 (range
1–6). Of the 49 patients, 4 (8.2%) discontinued this treatment:
the causes were grade 3 infection in two patients, grade 3
hepatic dysfunction in one patient, and patient refusal due
to grade 2 nausea in one patient. In addition, doses of doce-
taxel on day 15 were skipped in four patients because of
neutropenia, infection, or disease progression. Doses of
both docetaxel and S-1 administration were reduced in two
patients because of grade 4 neutropenia lasting 3 days or
neutropenic fever. Additionally, doses of S-1 were reduced
in 12 patients mainly because of diarrhea, vomiting, stoma-
titis, or infection. The next course of chemotherapy was
delayed after 12 (9.9%) of the 121 courses, mainly because
of neutropenia or diarrhea. In the 49 patients, dose intensi-
ties of docetaxel decreased in 19 patients (38.8%), and dose
intensities of S-1 decreased in 23 patients (46.9%). The
mean percentage of individual actually delivered doses per
planned doses was 94.1% for docetaxel and 92.7% for S-1.
Discussion
Several randomized phase III trials in patients with previ-
ously treated advanced NSCLC have demonstrated that
docetaxel or erlotinib prolongs survival and decreases
symptoms when compared with placebo [2, 3]. Moreover,
in patients with previously treated NSCLC pemetrexed or
geWtinib achieves eYcacy outcomes clinically equivalent to
those of docetaxel [19, 20]. Thus, docetaxel, pemetrexed,
geWtinib, or erlotinib is recommended as a second-line ther-
apy for advanced NSCLC [21]. However, the eYcacy
remains poor: reported response rates in unselective previ-
ously treated NSCLC are 6.7 to 10.8% with docetaxel,
9.1% with pemetrexed, 9.1% with geWtinib, and 8.9% with
erlotinib, and 1-year survival rates are 25 to 37% [2, 3, 5,
19,  20]. Therefore, further research should focus on the
development of regimens that are more eVective against
previously treated advanced NSCLC.
Table 2 Toxicity
National Cancer Institute-Common 
Terminology Criteria grade
T o x i c i t y 1234 5 3 – 5  ( % )
Leukopenia 1 13 14 4 0 36.7
Neutropenia 5 6 9 16 0 51.0
Thrombocytopenia 14 4 0 1 0 2.0
Anemia 19 20 9 1 0 20.4
Nausea 11 8 3 0 0 6.1
Vomiting 11 3 0 0 0 0
Anorexia 15 10 4 1 1 12.2
Stomatitis 8 8 3 0 0 6.1
Diarrhea 13 10 5 1 1 14.3
Dehydration 0 9 0 1 1 4.1
Infection 0 3 12 0 0 24.5
Elevation of serum creatinine 4 1 0 0 0 0
Elevation of aminotransferases 13 1 2 0 0 4.1
Hypokalemia 19 1 5 0 0 10.2
Hyponatremia 38 0 4 0 0 8.2
Fatigue or asthenia 8 7 3 0 0 6.1
Nail/skin toxicity 4 9 2 0 0 4.1
Table 3 Grade 3–5 toxicity according to age
70 years or 
older 
(n =1 6 )
Younger 
than 70 years 
(n =3 3 )
p
Leukopenia 5 (31.3%) 13 (39.4%) 0.579
Neutropenia 11 (68.8%) 14 (42.4%) 0.084
Anemia 4 (25%) 6 (18.9%) 0.583
Thrombocytopenia 1 (6.3%) 0 (0%) 0.147
Nausea 2 (12.5%) 1 (3.0%) 0.195
Stomatitis 3 (18.8%) 0 (0%) 0.01
Anorexia 4 (25.0%) 2 (6.1%) 0.058
Diarrhea 4 (25.0%) 3 (9.1%) 0.136
Dehydration 2 (12.5%) 0 (0%) 0.038
Infection 8 (50.0%) 4 (12.1%) 0.004796 Cancer Chemother Pharmacol (2011) 67:791–797
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In a recent phase III study in patients with previously
treated NSCLC, weekly docetaxel at a dose of 35 mg/m2
was similarly eYcacious as and better tolerated—speciW-
cally, incidences of grade 3–4 neutropenia and anemia were
lower—than a 3-weekly docetaxel at a dose of 75 mg/m2
[22]. On the other hand, in a phase II trial of biweekly doce-
taxel at a dose of 50 mg/m2 as second-line treatment in
patients with NSCLC, grade 3 or 4 neutropenia developed
in only 16% of patients [23]. Therefore, to reduce toxicity
we chose biweekly administration of docetaxel.
In the present study, the overall response rate in previ-
ously treated patients with a PS of 0–2 was 16.3% with a
MST of 9 months, a 1-year survival rate of 42%, and a
median PFS time of 3 months. Two previous studies have
reported that docetaxel at a dose of 40 mg/m2 on day 1 and
S-1 at a dose of 80 mg/m2 per day on days 1–14 every
3 weeks in patients with previously treated advanced
NSCLC and a PS of 0 or 1 achieved overall response rates
of 24.1 and 18.4% with MSTs of 11.8 months and
16.1 months, 1-year survival rates of 42 and 60%, and
median PFS times of 3.9 months and 4.4 months, respec-
tively [13,  14]. Our response and survival rates were
slightly lower than those of studies reported by Atagi et al.
and Yanagihara et al. [13, 14]. The reason might be that
neither previous report included patients with a PS of 2,
whereas our study included seven patients (14.3%) with a
PS of 2. Some previous trials have suggested that patients
with a PS of 2 have signiWcantly lower rates of response
and survival and higher rates of toxicity than do patients
with a PS of 0 or 1 [24, 25]. On the other hand, our results
compare favorably with those of most published trials of
the second-line treatment of NSCLC, although no conclu-
sions can be drawn from a direct comparison of the present
results with previous results. In previous randomized phase
III studies for previously treated NSCLC, overall response
rates have ranged from 6.7 to 20%, MSTs have ranged from
5.4 to 10.2 months, 1-year survival rates have ranged
from 19 to 45.6%, and median PFS times have ranged from
2.1–5.6 months [2, 5, 19, 22, 26–28].
We found that prior paclitaxel treatment status did not
signiWcantly aVect the response rate or the survival time.
Our results were consistent with those of previous phase III
trials of docetaxel [5, 22]. Therefore, this regimen including
docetaxel should be eVective in patients who have previ-
ously been treated with paclitaxel.
Pemetrexed has been reported to be eVective against
adenocarcinoma but not against squamous cell carcinoma
of the lung [29]. In addition, although patients with NSCLC
harboring an activating mutation in the EGFR gene respond
well to EGFR tyrosine kinase inhibitors, activating muta-
tions of the EGFR gene are present mostly in patients with
adenocarcinoma [30,  31]. Thus, options for second-line
treatment for patients with squamous cell carcinoma are
more limited than for patients with adenocarcinoma. In our
study, response rates and survival times did not diVer sig-
niWcantly with the histological type, although only small
numbers of patients were evaluated. Therefore, we believe
this regimen would be eVective regardless of the histological
type.
In the present study, grade 3–4 hematologic toxici-
ties, including neutropenia, developed in 51.0% of
patients, thrombocytopenia developed in 2.0%, and ane-
mia developed in 20.4%. In addition, grade 3–5 nonhe-
matologic toxicities included infection in 24.5% of
patients, anorexia in 12.2%, diarrhea in 14.3%, nausea in
6.1%, and dehydration in 4.2%. There was one treat-
ment-related death due to severe anorexia, stomatitis and
diarrhea, and, as consequence, dehydration. This patient
was a 71-year-old man. Grade 3–5 stomatitis, dehydra-
tion, and infection were signiWcantly more frequent in
patients 70 years or older than in patients younger than
70 years. Toxicities observed in this study were gener-
ally tolerable. However, the incidences of grade 3–4
neutropenia, anemia, and grade 3–5 diarrhea in our
study were higher than those of studies reported by
Atagi et al. and Yanagihara et al. or those in recently
published trials of single-agent docetaxel or pemetrexed,
whereas the incidences of the above toxicities in our
study were similar to or higher than those of previous
trials of the combination of docetaxel and gemcitabine
or irinotecan [2, 5, 13, 14, 19, 22, 26–28]. Zang et al.
[32] have reported that the dosages of the combination
of docetaxel and S-1 should be modiWed according to the
patient’s age, because grade 4 neutropenia or neutro-
penic fever occur more frequently in patients older than
60 years. In contrast, in a subset analysis of phase III tri-
als comparing single-agent pemetrexed with docetaxel
in patients with previously treated NSCLC, there was no
signiWcant diVerence in toxicity between patients
70 years or older and patients younger than 70 years
[33]. Thus, single-agent chemotherapy might be more
appropriate than doublet chemotherapy in previously
treated patients 70 years or older.
In conclusion, to our knowledge, the present phase II
study is the Wrst to examine the combination of S-1 and
biweekly docetaxel for previously treated advanced
N S C L C .  T h i s  t r e a t m e n t  i s  s a f e  a n d  e Vective in patients
with previously treated advanced NSCLC and is, there-
fore, an acceptable option in this setting regardless of the
histological type. A phase III study comparing docetaxel
alone to docetaxel plus S-1 in patients with previously
treated advanced NSCLC has begun enrollment in Japan to
determine whether adding S-1 to docetaxel is clinically
beneWcial.
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